Supplies of Wegovy and other weight loss drugs can now be tracked by patients

As Novo Nordisk and Eli Lilly struggle to keep up with growing demand for their popular diabetes and weight-loss drugs, healthcare companies are introducing supply trackers to help patients navigate ongoing shortages.

Growing sales for these drugs, known as GLP-1, have prompted Novo Nordisk and Eli Lilly to the most valuable pharmaceutical companies in the world. However, it has also made it difficult for some patients to fill their prescriptions.

A few doses of Wegovy, Zepbound and Mounjaro are all currently in limited supply due to increased demand, according to the US Food and Drug Administration (FDA).

Today, telehealth platform Ro launched it GLP-1 Tracer Supply allowing patients to sign up to receive alerts when a GLP-1 drug is back in supply in their area, including contact information for pharmacies where the drug is available.

“The challenges of GLP-1 deficiency are exacerbated by the lack of accurate, up-to-date and accessible GLP-1 supply information. Patients deserve better,” Ro co-founder and CEO Zachariah Reitano said in a press release.

The interactive tool uses Ro’s nationwide supply data, user-generated reports, and the latest information from the FDA.

In addition to receiving alerts, patients are also able to report details such as the drug, dosage and pharmacy where they did or did not find stock of a GLP-1 drug.

Eli Lilly, maker of Zepbound and Mounjaro, is developing a similar tool. The president of the company’s diabetes and obesity division Patrik Jonsson told Quartz that it is working on the update supply website with a heat map showing where patients can find their dose of Mounjaro and Zepbound.

“I understand that being a consumer today with all the supply constraints is not necessarily easy,” Jonsson said. “We are fully committed to not only increasing supply, but also making sure we are providing timely and appropriate information to consumers about medicines.”

Eli Lilly AND Novo Nordisk both have invested billions of dollars to ramp up production of their weight loss drugs, but in the short term patients are likely to still experience shortages.

“Even if we get our combined supply [medications] and competition, is not enough to meet the needs of 110 million Americans“, Jonsson said. You will most likely need one GLP-1 pill to meet the needs of 40% of American adults living with obesityhe added.

This article originally appeared on quartz.